TFF Pharmaceuticals (TFFP) 10-Q 11 May 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 08, 2023
Document Information Line Items
Entity Registrant Name	TFF Pharmaceuticals, Inc.
Trading Symbol	TFFP
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		36,193,085
Amendment Flag	false
Entity Central Index Key	0001733413
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39102
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4344737
Entity Address, Address Line One	1751 River Run
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Fort Worth
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	76107
City Area Code	(817)
Local Phone Number	438-6168
Title of 12(b) Security	Common stock: Par value $0.001
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 12,216,359	$ 16,612,315
Research and development tax incentive receivable	188,771	186,507
Prepaid assets and other current assets	1,555,309	2,226,344
Total current assets	13,960,439	19,025,166
Operating lease right-of-use asset, net	177,473	196,044
Property and equipment, net	2,226,399	3,078,342
Note receivable - Augmenta	1,839,692	1,812,975
Other assets	7,688	7,688
Total assets	18,211,691	24,120,215
Current liabilities:
Accounts payable	1,344,431	919,607
Accrued compensation		4,430
Deferred research grant revenue	151,000	126,000
Current portion of operating lease liability	81,412	80,625
Total current liabilities	1,576,843	1,130,662
Operating lease liability, net of current portion	91,524	110,094
Total liabilities	1,668,367	1,240,756
Commitments and contingencies (see Note 4)
Stockholders’ equity:
Common stock; $0.001 par value, 90,000,000 shares and 45,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively; 36,193,085 shares issued and outstanding	36,193	36,193
Additional paid-in capital	120,804,884	120,070,983
Accumulated other comprehensive loss	(157,964)	(139,295)
Accumulated deficit	(104,139,789)	(97,088,422)
Total stockholders’ equity	16,543,324	22,879,459
Total liabilities and stockholders’ equity	$ 18,211,691	$ 24,120,215

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	90,000,000	45,000,000
Common stock, shares issued	36,193,085	36,193,085
Common stock, shares outstanding	36,193,085	36,193,085

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Grant revenue	$ 51,429	$ 67,435
Operating expenses:
Research and development	4,018,659	5,237,424
General and administrative	3,119,216	3,213,198
Total operating expenses	7,137,875	8,450,622
Loss from operations	(7,086,446)	(8,383,187)
Other income:
Interest income	35,079	7,185
Total other income	35,079	7,185
Net loss	$ (7,051,367)	$ (8,376,002)
Net loss per share, basic (in Dollars per share)	$ (0.19)	$ (0.33)
Weighted average common shares outstanding, basic (in Shares)	36,193,085	25,371,781
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Net loss	$ (7,051,367)	$ (8,376,002)
Other comprehensive loss:
Foreign currency translation adjustments	(18,669)	47,234
Comprehensive loss	$ (7,070,036)	$ (8,328,768)

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Net loss per share, diluted	$ (0.19)	$ (0.33)
Weighted average common shares outstanding, diluted	36,193,085	25,371,781

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Stockholders’ Equity - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balance at Dec. 31, 2021	$ 25,372	$ 104,078,968	$ (48,921)	$ (65,318,360)	$ 38,737,059
Balance (in Shares) at Dec. 31, 2021	25,371,781
Stock-based compensation		1,177,702			1,177,702
Foreign currency translation adjustment			47,234		47,234
Net loss				(8,376,002)	(8,376,002)
Balance at Mar. 31, 2022	$ 25,372	105,256,670	(1,687)	(73,694,362)	31,585,993
Balance (in Shares) at Mar. 31, 2022	25,371,781
Balance at Dec. 31, 2022	$ 36,193	120,070,983	(139,295)	(97,088,422)	22,879,459
Balance (in Shares) at Dec. 31, 2022	36,193,085
Stock-based compensation		751,821			751,821
Costs related to ATM		(17,920)			(17,920)
Foreign currency translation adjustment			(18,669)		(18,669)
Net loss				(7,051,367)	(7,051,367)
Balance at Mar. 31, 2023	$ 36,193	$ 120,804,884	$ (157,964)	$ (104,139,789)	$ 16,543,324
Balance (in Shares) at Mar. 31, 2023	36,193,085

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (7,051,367)	$ (8,376,002)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	751,821	1,177,702
Interest accrued on note receivable	(26,717)
Write-off of construction-in-process	747,348
Depreciation and amortization	123,167	77,028
Changes in operating assets and liabilities:
Receivable due from collaboration agreement		(147,880)
Research and development tax incentive receivable	(24,906)	(108,097)
Prepaid assets and other current assets	685,328	237,646
Accounts payable	426,756	192,211
Accrued compensation	(4,430)	(416,910)
Deferred revenue	25,000	118,000
Operating lease obligation	(17,783)
Net cash used in operating activities	(4,365,783)	(7,246,302)
Cash flows from investing activities:
Purchases of property and equipment		(137,231)
Net cash used in investing activities		(137,231)
Cash flows from financing activities:
Payment of offering costs in connection with ATM	(17,920)
Net cash used in financing activities	(17,920)
Effect of exchange rate changes on cash and cash equivalents	(12,253)	3,031
Net change in cash and cash equivalents	(4,395,956)	(7,380,502)
Cash and cash equivalents at beginning of period	16,612,315	33,794,672
Cash and cash equivalents at end of period	12,216,359	26,414,170
Supplemental disclosure of non-cash investing and financing activities:
Purchases of equipment included in accounts payable		$ 338,674

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2023
Organization and Description of Business [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS TFF Pharmaceuticals, Inc. (the “Company”) was incorporated in the State of Delaware on January 24, 2018. The Company’s initial focus is on the development of inhaled dry powder drugs to enhance the treatment of pulmonary diseases and conditions. In December 2019, the Company established a wholly owned Australian subsidiary, TFF Pharmaceuticals Australia Pty Ltd (“TFF Australia”), in order to conduct clinical research. TFF Pharmaceuticals, Inc., along with TFF Australia, are collectively referred to as the “Company”. The Company is in the development stage and is devoting substantially all of its efforts toward technology research and development and the human clinical trials of its initial product candidates.

Going Concern and Management_s

Going Concern and Management’s Plans	3 Months Ended
	Mar. 31, 2023
Liquidity and Managements Plans [Abstract]
GOING CONCERN AND MANAGEMENT’S PLANS	NOTE 2 – GOING CONCERN AND MANAGEMENT’S PLANS The accompanying condensed consolidated financial statements have been prepared under the assumption the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. For the three months ended March 31, 2023 and 2022, the Company reported a net loss of $7.1 million and $8.4 million, respectively, and negative cash from operations of $4.4 million and $7.2 million, respectively. As of March 31, 2023, the Company had cash and cash equivalents of approximately $12.2 million, a working capital surplus of approximately $12.4 million and an accumulated deficit of $104.1 million. The Company has not generated revenues from commercial operations since inception and expects to continue incurring losses for the foreseeable future and needs to raise additional capital to continue the pursuit of its product development. Management believes that the Company does not have sufficient capital resources to sustain operations through at least the next twelve months from the date of this filing. Additionally, in view of the Company’s expectation to incur significant losses for the foreseeable future it will be required to raise additional capital resources in order to fund its operations, although the availability of, and the Company’s access to such resources, is not assured. Accordingly, management believes that there is substantial doubt regarding the Company’s ability to continue operating as a going concern through at least the next twelve months from the date of this filing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and with Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by GAAP for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2023 and the results of operations, changes in stockholders’ equity and cash flows for the periods presented. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Reclassification Certain prior period amounts have been reclassified to conform to the current period classification. Amounts received from the United States Internal Revenue Service (“IRS”) for payroll tax credits have been reclassified from other income to operating expenses in the condensed consolidated statements of operations to net the amounts with the related expense that was incurred with no changes in the previously reported net losses. Principles of Consolidation The consolidated financial statements include the accounts of TFF Pharmaceuticals, Inc. and its wholly owned subsidiary, TFF Australia. All material intercompany accounts and transactions have been eliminated in consolidation. Fair Value Option - Convertible Note Receivable The guidance in Accounting Standards Codification (“ASC”) 825, Financial Instruments The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Pursuant to this guidance, assets and liabilities are measured at fair value based, in part, on general economic and stock market conditions and those characteristics specific to the underlying investments. The carrying value is adjusted to estimated fair value at the end of each quarter, required to be reported separately in our condensed consolidated balance sheets from those instruments using another accounting method. Fair Value of Financial Instruments Authoritative guidance requires disclosure of the fair value of financial instruments. The Company measures the fair value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value which is not equivalent to cost will be classified and disclosed in one of the following three categories: Level 1 — Quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Research and Development Tax Incentive The Company is eligible to obtain a cash refund from the Australian Taxation Office for eligible research and development expenditures under the Australian R&D Tax Incentive Program (the “Australian Tax Incentive”). The Company recognizes the Australian Tax Incentive when there is reasonable assurance that the cash refund will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. As the Company has determined that it has reasonable assurance that it will receive the cash refund for eligible research and development expenditures, the Company records the Australian Tax Incentive as a reduction to research and development expenses as the Australian Tax Incentive is not dependent on the Company generating future taxable income, the Company’s ongoing tax status, or tax position. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time. This percentage of eligible research and development expenses reimbursable under the Australian Tax Incentive is 43.5% for the three months ended March 31, 2023 and 2022. In addition, the Company is also eligible to receive amounts from the United States Internal Revenue Service (“IRS”) related to research and development tax credits for expenditures. The research and development incentive receivable represents amounts due in connection with the Australian Tax Incentive and from the IRS. The Company has recorded a research and development tax incentive receivable of $188,771 and $186,507 as of March 31, 2023 and December 31, 2022, respectively, in the condensed consolidated balance sheets. The Company recorded a reduction to research and development expenses of $24,907 and $108,098 during the three months ended March 31, 2023 and 2022, respectively, for expenditures incurred during those respective periods. Basic and Diluted Earnings per Common Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods presented, all potentially dilutive securities are anti-dilutive. For the three months ended March 31, 2023 and 2022, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of diluted net loss per common share because inclusion thereof would be anti-dilutive: For The Three Months Ended 2023 2022 Stock Options 5,123,289 2,976,090 Warrants 5,747,792 389,233 10,871,081 3,365,323 * On an as-converted basis Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include the fair value of the convertible note receivable, stock-based compensation and warrants and the valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates. Risks and Uncertainties The Company’s business may be adversely affected by the continuing fallout from the COVID-19 pandemic. While the COVID-19 pandemic has abated in the last several months, many of the consequences of the COVID-19 pandemic continue to cause disruption and increased costs for businesses. In the case of clinical stage biopharmaceutical companies, the Company believes there continue to be, among other things, supply chain disruptions that are causing delays in the delivery of drug candidates and comparator products and healthcare staffing shortages that are causing delays in the establishment of test sites and the conduct of clinical trials. Potential impacts to the Company’s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees’ ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the supply of comparator products, the potential diversion of healthcare resources and staff away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company’s ability to raise capital and conduct business development activities. During 2020, the Company experienced a temporary suspension of dosing in the Phase I clinical trial for TFF TAC due to the COVID-19 pandemic and the pandemic has otherwise caused minor slowing in the timing of certain non-clinical and clinical activities by the Company and its collaborators and service providers during 2020 to date. However, the COVID-19 pandemic has not caused the Company to forego, abandon or materially delay any proposed activities. While the Company believes it has been able to effectively manage the disruption caused by the COVID-19 pandemic to date, there can be no assurance that its operations, including the development of its drug candidates, will not be disrupted or materially adversely affected in the future by the COVID-19 pandemic or an epidemic or outbreak of an infectious disease like the outbreak of COVID-19. Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging -Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity In June 2016, the FASB issued ASU 2016-13, Fin ancial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments adopted January 1, 2023 no The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the consolidated financial statements.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 4 - COMMITMENTS AND CONTINGENCIES Operating Leases In October 2018, the Company entered into a lease agreement for office space in Doylestown, Pennsylvania. The lease commenced on October 15, 2018 and expires on October 31, 2023, as amended. The lease has an additional one-year option for renewal, and the base rent is $37,080 per year. The Company has determined that the lease agreement is considered a short-term lease under ASC 842 and has not recorded a right-of-use asset or liability. The Company rents another office space on a month-to-month basis with no long-term commitment, which is considered a short-term lease as well. In May 2022, the Company entered into a lease agreement for lab space in Austin, Texas. The lease commenced on June 1, 2022 and expires on May 31, 2025. The lease has an additional three-year option for renewal, which the Company has determined it is not reasonably certain to exercise. Supplemental balance sheet information related to leases was as follows: March 31, Operating leases:  Operating lease right-of-use assets $ 177,473 Operating lease liability - current portion $ 81,412 Operating lease liability - long-term portion 91,524 Total operating lease liabilities $ 172,936 Supplemental lease expense related to leases was as follows: Statement of Operations For The Three Months Ended Lease Classification 2023 2022 Operating lease cost Research and development $ 22,275 $ - Short-term lease cost Research and development - 6,244 Short-term lease cost General and administrative 21,770 20,759 Total lease expense $ 44,045 $ 27,003 Other information related to operating leases: March 31, Weighted-average remaining lease term 2.2 years Weighted-average discount rate 8 % Supplemental cash flow information related to operating leases was as follows: For The Three Months Ended 2023 2022 Cash paid for operating lease liabilities $ 21,488 $ - Approximate future minimum lease payments under non-cancellable leases (including short-term leases) are as follows: Fiscal Year Ending December 31, 2023 (Remaining) $ 81,000 2024 91,000 2025 38,000 Total minimum lease payments 210,000 Less: Imputed interest (16,000 ) Total $ 194,000 Legal The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes and are not predictable with assurance. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its business and financial condition. To the Company’s knowledge, neither the Company nor any of its properties are subject to any pending legal proceedings.

License and Agreements

License and Agreements	3 Months Ended
	Mar. 31, 2023
License And Agreement Disclosure Abstract
LICENSE AND AGREEMENTS	NOTE 5 - LICENSE AND AGREEMENTS In July 2015, the University of Texas at Austin (“UT”) granted to the Company’s former parent, LTI, an exclusive worldwide, royalty bearing license to the patent rights for the TFF platform in all fields of use, other than vaccines for which LTI received a non-exclusive worldwide, royalty bearing license to the patent rights for the TFF platform. In March 2018, LTI completed an assignment to the Company all of its interest to the TFF platform, including the patent license agreement with UT, at which time the Company paid UT an assignment fee of $100,000 in accordance with the patent license agreement. In November 2018, the Company and UT entered into an amendment to the patent license agreement pursuant to which, among other things, the Company’s exclusive patent rights to the TFF platform were expanded to all fields of use, and in March 2022 the Company and UT entered into an amended and restated patent license agreement for purposes of further strengthening the Company’s license rights, including the Company’s exclusive right to license all future UT patents relating to the TFF technology and all know-how held by UT relating to the TFF technology . The patent license agreement requires the Company to pay royalties and milestone payments and conform to a variety of covenants and agreements, and in the event of the Company’s breach of agreement, UT may elect to terminate the agreement. For the period ended December 31, 2018, the Company did not achieve any of the milestones and, as such, was not required to make any milestone payments. During the ended December 31, 2019, the Company achieved one milestone by gaining IND approval on first indication of a licensed product on November 24, 2019 and the Company satisfied the milestone payment of $50,000 and issuance of shares in accordance with the agreement. As of the date of these condensed consolidated financial statements, the Company is in compliance with the patent license agreement as all required amounts have been paid in accordance with the agreement. In May 2018, the Company entered into a master services agreement and associated individual study contracts with ITR Canada, Inc. (“ITR”) to provide initial contract pre-clinical research and development services for the Company’s drug product candidates. In January 2019, the Company cancelled all of the individual study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (“SPI”)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits. The services related to the contract with SPI were sub-contracted to ITR and others under substantially the same terms as the initial contract with ITR. Desire Ventures, LLC facilitates the invoicing for the various affiliates. The accounts payable due in connection with this agreement was approximately $0 as of March 31, 2023 and December 31, 2022. During the three months ended March 31, 2023 and 2022, the Company recorded research and development costs of approximately $0 and $1,585,000, respectively, pertaining to this agreement. In April 2019, the Company entered into a master services agreement with Societal CDMO (formally known as Irisys, LLC) to provide contract manufacturing services for one of the Company’s drug product candidates, TFF VORI. The Company had a credit due in connection with this agreement of approximately $2,000 and $25,000 as of March 31, 2023 and December 31, 2022, respectively. During the three months ended March 31, 2023 and 2022, the Company recorded research and development costs of approximately $24,000 and $446,000, respectively. In January 2020, TFF Australia entered into a master consultancy agreement with Novotech (Australia) Pty Ltd. (formally known as Clinical Network Services Pty Ltd.) to provide initial contract clinical research and development services for the Company’s drug product candidates. The accounts payable due in connection with this agreement was approximately AUD$59,000 (US$40,000) and AUD$22,000 (US$15,000) as of March 31, 2023 and December 31, 2022, respectively. During the three months ended March 31, 2023 and 2022, the Company recorded research and development costs of approximately AUD$84,000 (US$57,000) and AUD$347,000 (US$251,000), respectively, pertaining to this agreement. On August 12, 2020, the Company entered into a licensing and collaboration agreement with UNION Therapeutics A/S pursuant to which UNION acquired an option to obtain a worldwide exclusive license for the TFF technology formulated niclosamide. In the first quarter of 2022, the Company completed a Phase 1 clinical trial of TFF Niclosamide. The Company and Therapeutics have not further progressed TFF Niclosamide pending the parties’ further review of the Phase 1 results, animal data, and anti-viral market opportunities. In January 2021, the Company entered into a master services agreement with Experic to provide contract manufacturing services for one of the Company’s drug product candidates, TFF VORI. The accounts payable due in connection with this agreement was approximately $307,000 and $176,000 as of March 31, 2023 and December 31, 2022, respectively. During the three months ended March 31, 2023 and 2022, the Company recorded research and development costs of approximately $472,000 and $318,000, respectively, pertaining to this agreement. In 2022, the Company entered into a Master Services Agreement with Synteract, Inc. to provide contract research and development services for one of the Company’s drug product candidates, TFF VORI. The accounts payable due in connection with this agreement was approximately $91,000 and $191,000 as of March 31, 2023 and December 31, 2022, respectively. During the three months ended March 31, 2023 and 2022, the Company recorded research and development costs of approximately $341,000 and $226,000, respectively. Joint Development Agreement On November 2, 2020, the Company and Augmenta entered into the JDA pursuant to which the Company and Augmenta (collectively the “Parties”) agreed to work jointly to develop one or more novel commercial products incorporating Augmenta’s human derived monoclonal antibody for the treatment of patients with COVID-19 and the Company’s patented Thin Film Freezing technology platform. Each party retains full ownership over its existing assets. The Parties agreed to share development costs with each party funding its fifty-percent-share at specified times. The JDA is within the scope of ASC 808 as the Company and Augmenta are both active participants in the research and development activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. The research and development activities are a unit of account under the scope of ASC 808 and are not promises to a customer under the scope of ASC 606. The Company records its portion of the research and development expenses as the related expenses are incurred. All payments received or amounts due from Augmenta for reimbursement of shared costs are accounted for as an offset to research and development expense. During the three months ended March 31, 2022, the Company recorded research and development expenses of $147,880. Effective January 1, 2023, the Company and Augmenta entered into a convertible note purchase agreement (“Augmenta Note”) in which the receivable of $1,812,975 due from Augmenta was converted into a convertible note receivable (see Note 6). The Augmenta Note satisfies Augmenta’s requirement to fund its fifty-percent-share of the development costs under the JDA. In addition, the Company and Augmenta agreed to suspend the development work under the JDA.

Convertible Note Receivable _ A

Convertible Note Receivable – Augmenta	3 Months Ended
	Mar. 31, 2023
Receivables [Abstract]
CONVERTIBLE NOTE RECEIVABLE – AUGMENTA	NOTE 6 - CONVERTIBLE NOTE RECEIVABLE – AUGMENTA Effective January 1, 2023, the Company and Augmenta entered into a convertible note purchase agreement pursuant to which a receivable due from Augmenta in connection with the JDA was converted into the Augmenta Note (see Note 5). Under the terms of the Augmenta Note, Augmenta agreed to pay the principal amount of $1,812,975 to the Company. The Augmenta Note accrues interest at a rate of 6% per annum and has a maturity date of the earlier of (i) January 1, 2026 (“Maturity Date”), or (ii) upon the occurrence and during the continuance of an event of default. Accrued interest shall be payable at maturity. The Company has the following optional conversion rights under the Augmenta Note: ● The Company may convert, at any time and at its option, all outstanding principal and accrued and unpaid interest into shares of Augmenta common stock at a price per share equal to an amount obtained by dividing $15,000,000 by the number of outstanding shares of Augmenta common stock on a fully diluted basis (“Conversion Price”). ● If Augmenta completes a private placement sale of its preferred stock in the amount less than $15,000,000, the Company may convert, at its option, all outstanding principal and accrued and unpaid interest into shares of the same security in such financing at a per share price equal to the lower of the Conversion Price or the price per share sold in the financing. In addition, the outstanding principal and accrued and unpaid interest under the Augmenta Note will automatically convert in the following scenarios: ● If Augmenta completes a financing with gross proceeds of at least $15,000,000 (“Qualified Financing”) on or before the Maturity Date, then the outstanding principal and accrued and unpaid interest shall automatically convert into the same security at a price per share equal to the lower of the Conversion Price or the price per share sold in the Qualified Financing. ● If Augmenta completes an underwritten public offering with gross proceeds of at least $35,000,000 (“Qualified IPO”) on or before the Maturity Date, then the outstanding principal and accrued and unpaid interest shall automatically convert into the same security at a price per share equal to the lower of the Conversion Price or the price per share sold in the Qualified IPO. ● If a change of control occurs prior to the payment in full of the principal amount of the Augmenta Note, then the Company will be paid all outstanding principal and accrued and unpaid interest, plus a premium of 100% of the outstanding principal. The Company has elected to measure the Augmenta Note at fair value in accordance with ASC 825 (see Note 7).

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	3 Months Ended
	Mar. 31, 2023
Fair Value of Financial Assets and Liabilities [Abstract]
FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES	NOTE 7 - FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES The carrying value of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value because of their short-term nature. The Augmenta Note is held at fair value. The following table presents the Company’s assets and liabilities that are measured at fair value as of March 31, 2023: Fair value measured as of March 31, 2023 Total at Quoted Significant Significant 2023 (Level 1) (Level 2) (Level 3) Assets Augmenta Note at fair value $ 1,839,692 $ - $ - $ 1,839,692 Level 3 Measurement The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis: Fair Value of Level 3 March 31, Beginning balance $ 1,812,975 Accrued interest receivable 26,717 Change in fair value - Ending balance $ 1,839,692 The fair value of the Augmenta Note is measured using Level 3 (unobservable) inputs. The Company determined the fair value for the Augmenta Note using a probability weighted-scenario valuation model with the assistance of a third-party valuation specialist. The unobservable inputs include estimates of the equity value of Augmenta and the timing and probability of future financing events, optional conversion to common stock, and repayment at maturity. The conversion upon a qualified financing scenario valued the Augmenta Note based on a bond plus call option model. The optional conversion to common stock valued the Augmenta Note based on the present value of common stock, determined using an adjusted net assets method and option-pricing model, and implied number of common shares upon conversion. The repayment upon maturity is based on the total principal and accrued interest through the maturity date.

Stock Based Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
STOCK BASED COMPENSATION	NOTE 8 - STOCK BASED COMPENSATION In January 2018, the Company’s board of directors approved its 2018 Stock Incentive Plan (“2018 Plan”). The 2018 Plan provides for the grant of non-qualified stock options and incentive stock options to purchase shares of the Company’s common stock, the grant of restricted and unrestricted share awards and grant of restricted stock units. The Company initially reserved 1,630,000 shares of its common stock under the 2018 Plan; however, upon completion of the Company’s IPO the number of shares reserved for issuance under the 2018 Plan increased to 3,284,480, representing 15% of the Company’s outstanding shares of common stock calculated on a fully diluted basis upon the close of the IPO. All of the Company’s employees and any subsidiary employees (including officers and directors who are also employees), as well as all of the Company’s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will be eligible to receive incentive awards under the 2018 Plan. In September 2021, the Company’s board of directors approved its 2021 Stock Incentive Plan (“2021 Plan”), which was also approved by the stockholders of the Company at the Company’s annual meeting of stockholders held on November 4, 2021. The 2021 Plan provides for the grant of non-qualified stock options and incentive stock options to purchase shares of the Company’s common stock, the grant of restricted and unrestricted share awards and grant of restricted stock units. The Company has 4,200,000 shares of its common stock reserved under the 2021 Plan. All of the Company’s employees and any subsidiary employees (including officers and directors who are also employees), as well as all of the Company’s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will be eligible to receive incentive awards under the 2021 Plan. The following table summarizes the stock-based compensation expense recorded in the Company’s results of operations during the three months ended March 31, 2023 and 2022 for stock options and warrants: For The Three Months Ended 2023 2022 Research and development $ 243,874 $ 205,809 General and administrative 507,947 971,893 $ 751,821 $ 1,177,702 As of March 31, 2023, there was approximately $6,304,000 of total unrecognized compensation expense related to non-vested share-based compensation arrangements that are expected to vest. This cost is expected to be recognized over a weighted-average period of 2.0 years. The Company records compensation expense for awards with graded vesting using the straight-line method. The Company recognizes compensation expense over the requisite service period applicable to each individual award, which generally equals the vesting term. The Company estimates the fair value of each option award using the Black-Scholes-Merton option pricing model. Forfeitures are recognized when realized. The Company estimated the fair value stock options using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service periods of the respective awards. The fair value of stock options issued was estimated using the following: For The Three Months Weighted average exercise price $ 1.11 Weighted average grant date fair value $ 0.73 Assumptions Expected volatility 95%-96 % Expected term (in years) 6.3 - 6.9 Risk-free interest rate 3.54%-3.79 % Expected dividend yield 0.00 % The risk-free interest rate was obtained from U.S. Treasury rates for the applicable periods. The Company’s expected volatility was based upon the historical volatility for industry peers and used an average of those volatilities. The expected life of the Company’s options was determined using the simplified method as a result of limited historical data regarding the Company’s activity for employee awards and the contractual term for nonemployee awards. The dividend yield considers that the Company has not historically paid dividends, and does not expect to pay dividends in the foreseeable future. The Company uses the closing stock price on the date of grant as the fair value of the common stock. The following table summarizes stock option activity during the three months ended March 31, 2023: Number of Weighted- Weighted- Intrinsic Outstanding at January 1, 2023 2,909,057 $ 5.96 7.46 $ 24,279 Granted 2,529,950 1.11 - - Cancelled (315,718 ) 7.34 - - Outstanding at March 31, 2023 5,123,289 $ 3.48 8.48 $ - Exercisable at March 31, 2023 1,616,378 $ 5.30 6.46 $ - The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had strike prices lower than the fair value of the Company’s common stock.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 - SUBSEQUENT EVENTS The Company has performed an evaluation of events occurring subsequent to March 31, 2023 through the filing date of this Quarterly Report. Based on its evaluation, there are no events that need to be disclosed.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and with Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by GAAP for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2023 and the results of operations, changes in stockholders’ equity and cash flows for the periods presented. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to the current period classification. Amounts received from the United States Internal Revenue Service (“IRS”) for payroll tax credits have been reclassified from other income to operating expenses in the condensed consolidated statements of operations to net the amounts with the related expense that was incurred with no changes in the previously reported net losses.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of TFF Pharmaceuticals, Inc. and its wholly owned subsidiary, TFF Australia. All material intercompany accounts and transactions have been eliminated in consolidation.
Fair Value Option - Convertible Note Receivable	Fair Value Option - Convertible Note Receivable The guidance in Accounting Standards Codification (“ASC”) 825, Financial Instruments The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Pursuant to this guidance, assets and liabilities are measured at fair value based, in part, on general economic and stock market conditions and those characteristics specific to the underlying investments. The carrying value is adjusted to estimated fair value at the end of each quarter, required to be reported separately in our condensed consolidated balance sheets from those instruments using another accounting method.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Authoritative guidance requires disclosure of the fair value of financial instruments. The Company measures the fair value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value which is not equivalent to cost will be classified and disclosed in one of the following three categories: Level 1 — Quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Research and Development Tax Incentive	Research and Development Tax Incentive The Company is eligible to obtain a cash refund from the Australian Taxation Office for eligible research and development expenditures under the Australian R&D Tax Incentive Program (the “Australian Tax Incentive”). The Company recognizes the Australian Tax Incentive when there is reasonable assurance that the cash refund will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. As the Company has determined that it has reasonable assurance that it will receive the cash refund for eligible research and development expenditures, the Company records the Australian Tax Incentive as a reduction to research and development expenses as the Australian Tax Incentive is not dependent on the Company generating future taxable income, the Company’s ongoing tax status, or tax position. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time. This percentage of eligible research and development expenses reimbursable under the Australian Tax Incentive is 43.5% for the three months ended March 31, 2023 and 2022. In addition, the Company is also eligible to receive amounts from the United States Internal Revenue Service (“IRS”) related to research and development tax credits for expenditures. The research and development incentive receivable represents amounts due in connection with the Australian Tax Incentive and from the IRS. The Company has recorded a research and development tax incentive receivable of $188,771 and $186,507 as of March 31, 2023 and December 31, 2022, respectively, in the condensed consolidated balance sheets. The Company recorded a reduction to research and development expenses of $24,907 and $108,098 during the three months ended March 31, 2023 and 2022, respectively, for expenditures incurred during those respective periods.
Basic and Diluted Earnings per Common Share	Basic and Diluted Earnings per Common Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods presented, all potentially dilutive securities are anti-dilutive. For the three months ended March 31, 2023 and 2022, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of diluted net loss per common share because inclusion thereof would be anti-dilutive: For The Three Months Ended 2023 2022 Stock Options 5,123,289 2,976,090 Warrants 5,747,792 389,233 10,871,081 3,365,323 * On an as-converted basis
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include the fair value of the convertible note receivable, stock-based compensation and warrants and the valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.
Risks and Uncertainties	Risks and Uncertainties The Company’s business may be adversely affected by the continuing fallout from the COVID-19 pandemic. While the COVID-19 pandemic has abated in the last several months, many of the consequences of the COVID-19 pandemic continue to cause disruption and increased costs for businesses. In the case of clinical stage biopharmaceutical companies, the Company believes there continue to be, among other things, supply chain disruptions that are causing delays in the delivery of drug candidates and comparator products and healthcare staffing shortages that are causing delays in the establishment of test sites and the conduct of clinical trials. Potential impacts to the Company’s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees’ ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the supply of comparator products, the potential diversion of healthcare resources and staff away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company’s ability to raise capital and conduct business development activities. During 2020, the Company experienced a temporary suspension of dosing in the Phase I clinical trial for TFF TAC due to the COVID-19 pandemic and the pandemic has otherwise caused minor slowing in the timing of certain non-clinical and clinical activities by the Company and its collaborators and service providers during 2020 to date. However, the COVID-19 pandemic has not caused the Company to forego, abandon or materially delay any proposed activities. While the Company believes it has been able to effectively manage the disruption caused by the COVID-19 pandemic to date, there can be no assurance that its operations, including the development of its drug candidates, will not be disrupted or materially adversely affected in the future by the COVID-19 pandemic or an epidemic or outbreak of an infectious disease like the outbreak of COVID-19.
Recent Accounting Standards	Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging -Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity In June 2016, the FASB issued ASU 2016-13, Fin ancial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments adopted January 1, 2023 no The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Schedule of potential common stock equivalents outstanding	For The Three Months Ended 2023 2022 Stock Options 5,123,289 2,976,090 Warrants 5,747,792 389,233 10,871,081 3,365,323

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of supplemental balance sheet information related to leases	March 31, Operating leases:  Operating lease right-of-use assets $ 177,473 Operating lease liability - current portion $ 81,412 Operating lease liability - long-term portion 91,524 Total operating lease liabilities $ 172,936
Schedule of supplemental lease expense related to leases	Statement of Operations For The Three Months Ended Lease Classification 2023 2022 Operating lease cost Research and development $ 22,275 $ - Short-term lease cost Research and development - 6,244 Short-term lease cost General and administrative 21,770 20,759 Total lease expense $ 44,045 $ 27,003
Schedule of other information related to operating leases	March 31, Weighted-average remaining lease term 2.2 years Weighted-average discount rate 8 %
Schedule of supplemental cash flow information related to operating leases	For The Three Months Ended 2023 2022 Cash paid for operating lease liabilities $ 21,488 $ -
Schedule of future minimum lease payments under non-cancellable leases	Fiscal Year Ending December 31, 2023 (Remaining) $ 81,000 2024 91,000 2025 38,000 Total minimum lease payments 210,000 Less: Imputed interest (16,000 ) Total $ 194,000

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value of Financial Assets and Liabilities [Abstract]
Schedule of company’s assets and liabilities that are measured at fair value	Fair value measured as of March 31, 2023 Total at Quoted Significant Significant 2023 (Level 1) (Level 2) (Level 3) Assets Augmenta Note at fair value $ 1,839,692 $ - $ - $ 1,839,692
Schedule of fair value of the company’s Level 3 financial assets	Fair Value of Level 3 March 31, Beginning balance $ 1,812,975 Accrued interest receivable 26,717 Change in fair value - Ending balance $ 1,839,692

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of stock-based compensation expense	For The Three Months Ended 2023 2022 Research and development $ 243,874 $ 205,809 General and administrative 507,947 971,893 $ 751,821 $ 1,177,702
Schedule of fair value of employee stock options	For The Three Months Weighted average exercise price $ 1.11 Weighted average grant date fair value $ 0.73 Assumptions Expected volatility 95%-96 % Expected term (in years) 6.3 - 6.9 Risk-free interest rate 3.54%-3.79 % Expected dividend yield 0.00 %
Schedule of stock option activity	Number of Weighted- Weighted- Intrinsic Outstanding at January 1, 2023 2,909,057 $ 5.96 7.46 $ 24,279 Granted 2,529,950 1.11 - - Cancelled (315,718 ) 7.34 - - Outstanding at March 31, 2023 5,123,289 $ 3.48 8.48 $ - Exercisable at March 31, 2023 1,616,378 $ 5.30 6.46 $ -

Going Concern and Management__2

Going Concern and Management’s Plans (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Going Concern and Management’s Plans [Abstract]
Net loss	$ 7.1	$ 8.4
Negative cash from operations	4.4	$ 7.2
Cash and cash equivalents	12.2
Working capital surplus	12.4
Accumulated deficit	$ 104.1

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Research and development tax percentage	43.50%
Research and development tax	$ 188,771	$ 147,880	$ 186,507
Research and development expenses	$ 24,907		$ 108,098

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Line Items]
Potential common stock equivalents outstanding	10,871,081	3,365,323
Stock Options [Member]
Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Line Items]
Potential common stock equivalents outstanding	5,123,289	2,976,090
Warrants [Member]
Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Line Items]
Potential common stock equivalents outstanding	5,747,792	389,233

Commitments and Contingencies_2

Commitments and Contingencies (Details)	1 Months Ended
	Oct. 31, 2018 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Rent expenses	$ 37,080

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of supplemental balance sheet information related to leases	3 Months Ended
	Mar. 31, 2023 USD ($)
Operating leases:
Operating lease right-of-use assets	$ 177,473
Operating lease liability - current portion	81,412
Operating lease liability - long-term portion	91,524
Total operating lease liabilities	$ 172,936

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of supplemental lease expense related to leases - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Total lease expense	$ 44,045	$ 27,003
Research and development [Member]
Segment Reporting Information [Line Items]
Operating lease cost	22,275
Short-term lease cost		6,244
General and administrative [Member]
Segment Reporting Information [Line Items]
Short-term lease cost	$ 21,770	$ 20,759

Commitments and Contingencies_5

Commitments and Contingencies (Details) - Schedule of other information related to operating leases	Mar. 31, 2023
Schedule of Other Information Related to Operating Leases [Abstract]
Weighted-average remaining lease term	2 years 2 months 12 days
Weighted-average discount rate	8%

Commitments and Contingencies_6

Commitments and Contingencies (Details) - Schedule of supplemental cash flow information related to operating leases - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Schedule of Supplemental Cash Flow Information Related to Operating Leases [Abstract]
Cash paid for operating lease liabilities	$ 21,488

Commitments and Contingencies_7

Commitments and Contingencies (Details) - Schedule of future minimum lease payments under non-cancellable leases	Mar. 31, 2023 USD ($)
Schedule of Future Minimum Lease Payments under Non Cancellable Leases [Abstract]
2023	$ 81,000
2024	91,000
2025	38,000
Total minimum lease payments	210,000
Less: Imputed interest	(16,000)
Total	$ 194,000

License and Agreements (Details

License and Agreements (Details)		1 Months Ended			3 Months Ended				12 Months Ended
	Jan. 01, 2023 USD ($)	Jan. 31, 2020	Nov. 24, 2019 USD ($)	Jan. 31, 2019	Mar. 31, 2023 USD ($)	Mar. 31, 2023 AUD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2022 AUD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2018 USD ($)
License and Agreements (Details) [Line Items]
Assignment fee										$ 100,000
Milestone payment			$ 50,000
Accounts payable due					$ 0				$ 0
Recorded research and development costs					24,907				108,098
Accounts payable agreement					2,000				25,000
Research and development expenses					188,771		$ 147,880		186,507
Research and development costs					472,000		318,000
Cash receivable	$ 1,812,975
Master Services Agreement [Member]
License and Agreements (Details) [Line Items]
Agreement term, description				In January 2019, the Company cancelled all of the individual study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (“SPI”)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits.
Accounts payable due					307,000				176,000
Recorded research and development costs					0		1,585,000
Master Services Agreement with Societal [Member]
License and Agreements (Details) [Line Items]
Research and development expenses					24,000		446,000
Master Consultancy Agreement [Member]
License and Agreements (Details) [Line Items]
Research and development expenses							251,000	$ 347,000
Agreement description		to provide initial contract clinical research and development services for the Company’s drug product candidates. The accounts payable due in connection with this agreement was approximately AUD$59,000 (US$40,000) and AUD$22,000 (US$15,000) as of March 31, 2023 and December 31, 2022, respectively.
Contract manufacturing services [Member] | Master Services Agreement [Member]
License and Agreements (Details) [Line Items]
Accounts payable due					91,000				$ 191,000
Recorded research and development costs					341,000		$ 226,000
Clinical Network Services Pty Ltd. [Member]
License and Agreements (Details) [Line Items]
Research and development expenses					$ 57,000	$ 84,000

Convertible Note Receivable __2

Convertible Note Receivable – Augmenta (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Convertible Note Receivable – Augmenta (Details) [Line Items]
Principal amount	$ 1,812,975
Accrues interest rate	6%
Outstanding principal amount	$ 15,000,000
Outstanding principal interest percentage	100%
Qualified Financing [Member]
Convertible Note Receivable – Augmenta (Details) [Line Items]
Gross proceeds	$ 15,000,000
Qualified IPO [Member]
Convertible Note Receivable – Augmenta (Details) [Line Items]
Gross proceeds	35,000,000
Private Placement [Member]
Convertible Note Receivable – Augmenta (Details) [Line Items]
Outstanding principal amount	$ 15,000,000

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities (Details) - Schedule of company’s assets and liabilities that are measured at fair value	Mar. 31, 2023 USD ($)
Assets
Augmenta Note at fair value	$ 1,839,692
Level 1 [Member]
Assets
Augmenta Note at fair value
Level 2 [Member]
Assets
Augmenta Note at fair value
Level 3 [Member]
Assets
Augmenta Note at fair value	$ 1,839,692

Fair Value of Financial Asset_4

Fair Value of Financial Assets and Liabilities (Details) - Schedule of fair value of the company’s Level 3 financial assets - Level 3 [Member]	3 Months Ended
	Mar. 31, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 1,812,975
Accrued interest receivable	26,717
Change in fair value
Ending balance	$ 1,839,692

Stock Based Compensation (Detai

Stock Based Compensation (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2018	Mar. 31, 2023	Sep. 30, 2021
Stock Based Compensation (Details) [Line Items]
Common stock			4,200,000
Unrecognized compensation expense (in Dollars)		$ 6,304,000
Weighted-average period		2 years
IPO [Member]
Stock Based Compensation (Details) [Line Items]
Shares reserved for issuance	1,630,000
Common stock	3,284,480
Outstanding percentage	15%

Stock Based Compensation (Det_2

Stock Based Compensation (Details) - Schedule of stock-based compensation expense - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Stock based compensation expense	$ 751,821	$ 1,177,702
Research and development [Member]
Stock Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Stock based compensation expense	243,874	205,809
General and administrative [Member]
Stock Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Stock based compensation expense	$ 507,947	$ 971,893

Stock Based Compensation (Det_3

Stock Based Compensation (Details) - Schedule of fair value of employee stock options	3 Months Ended
	Mar. 31, 2023 $ / shares
Stock Based Compensation (Details) - Schedule of fair value of employee stock options [Line Items]
Weighted average exercise price (in Dollars per share)	$ 1.11
Weighted average grant date fair value (in Dollars per share)	$ 0.73
Assumptions
Expected dividend yield	0%
Minimum [Member]
Assumptions
Expected volatility	95%
Expected term (in years)	6 years 3 months 18 days
Risk-free interest rate	3.54%
Maximum [Member]
Assumptions
Expected volatility	96%
Expected term (in years)	6 years 10 months 24 days
Risk-free interest rate	3.79%

Stock Based Compensation (Det_4

Stock Based Compensation (Details) - Schedule of stock option activity	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Schedule of Stock Option Activity [Abstract]
Number of Shares, Outstanding, Outstanding ending balance | shares	2,909,057
Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance | $ / shares	$ 5.96
Weighted-Average Remaining Contractual Term, Outstanding ending balance	7 years 5 months 15 days
Intrinsic Value, Outstanding ending balance | $	$ 24,279
Number of Shares, Outstanding, Granted | shares	2,529,950
Weighted-Average Exercise Prices, Outstanding, Granted | $ / shares	$ 1.11
Weighted-Average Remaining Contractual Term, Granted
Intrinsic Value, Granted | $
Number of Shares, Cancelled | shares	(315,718)
Weighted-Average Exercise Prices, Outstanding, Cancelled | $ / shares	$ 7.34
Weighted-Average Remaining Contractual Term, Cancelled
Intrinsic Value, Cancelled | $
Number of Shares, Outstanding, Outstanding ending balance | shares	5,123,289
Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance | $ / shares	$ 3.48
Weighted-Average Remaining Contractual Term, Outstanding ending balance	8 years 5 months 23 days
Intrinsic Value, Outstanding ending balance | $
Number of Shares, Outstanding, Exercisable | shares	1,616,378
Weighted-Average Exercise Prices, Outstanding, Exercisable | $ / shares	$ 5.3
Weighted-Average Remaining Contractual Term, Exercisable	6 years 5 months 15 days
Intrinsic Value, Exercisable | $

Subsequent Events (Details)

Subsequent Events (Details)	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Maturity date	Mar. 31, 2023